SMAIOXPAR:ALSMA -0.23%79 EBIT per Share is €-0.46 as of Dec. 2025. GuruFocus rates XPAR:ALSMA with a GF Score™ of 79/100 and a GF Value™ of €7.64 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 529 Healthcare Providers & Services companies, SMAIO ranks better than 53.31% on this metric.
SMAIO's EBIT per Share for the
six
months ended in Dec. 2025 was €-0.29.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.46.
During the past 3 years, the average EBIT per Share Growth Rate was 14.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 3.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for SMAIO's EBIT per Share or its related term are showing as below:
XPAR:ALSMA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -78.5 Med: 1.7 Max: 23
Current: 14.3
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of SMAIO was 23.00% per year. The lowest was -78.50% per year. And the median was 1.70% per year.
XPAR:ALSMA's 3-Year EBIT Growth Rate is ranked better than 53.31% of 529
companies
in the Healthcare Providers & Services industry
Industry Median: 12.1
vs XPAR:ALSMA: 14.30
SMAIO's EBIT for the
six
months ended in Dec. 2025 was €-1.63 Mil.
SMAIO (XPAR:ALSMA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
SMAIO EBIT per Share Related Terms
SMAIO EBIT per Share Historical Data
* Premium members only.
The historical data trend for SMAIO's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.46
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SMAIO (XPAR:ALSMA) has a EBIT per Share of €-0.46 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on SMAIO and its competitors. According to the industry distribution chart, SMAIO ranks #247 out of 529 companies in the Healthcare Providers & Services industry, placing it in the top 46.7%.
Is SMAIO's EBIT per Share too high?
SMAIO's current EBIT per Share is €-0.46. Based on the distribution chart, SMAIO ranks #247 out of 529 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, SMAIO has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SMAIO's EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, SMAIO ranks #247 out of 529 companies for EBIT per Share. This puts SMAIO in the upper half of its industry. The industry median EBIT per Share is 12.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.10, based on 529 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on SMAIO and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SMAIO's current EBIT per Share is €-0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SMAIO stock overvalued right now?
Based on GuruFocus' analysis, SMAIO (XPAR:ALSMA) is currently considered Modestly Overvalued. The stock's GF Value™ is €7.64, compared to a current price of €8.50 — trading 11.3% above its estimated fair value. The current EBIT per Share is €-0.46. SMAIO's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For SMAIO (XPAR:ALSMA), the current EBIT per Share is €-0.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SMAIO (XPAR:ALSMA) Overvalued in 2026?
Based on GuruFocus' analysis, SMAIO stock appears to be overvalued.
The current stock price of €8.50 is trading 11.3% above its estimated GF Value™ of €7.64.
GuruFocus considers SMAIO to be Modestly Overvalued.
Key valuation signals for XPAR:ALSMA:
EBIT per Share: €-0.46
GF Value™: €7.64 vs. price of €8.50 (11.3% above fair value)
No single metric tells the full story. See the XPAR:ALSMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SMAIO SA is engaged in offering spine surgeons a complete solution, consisting of software, implantable devices, and associated services, to treat spinal pathologies requiring surgery.
79GF Score
Get the complete analysis for XPAR:ALSMA
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALSMA has been successfully added to your 
